156 related articles for article (PubMed ID: 38125697)
21. Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis.
Black M; Barsoum IB; Truesdell P; Cotechini T; Macdonald-Goodfellow SK; Petroff M; Siemens DR; Koti M; Craig AW; Graham CH
Oncotarget; 2016 Mar; 7(9):10557-67. PubMed ID: 26859684
[TBL] [Abstract][Full Text] [Related]
22. Doxorubicin resistance in breast cancer xenografts and cell lines can be counterweighted by microRNA-140-3p, through PD-L1 suppression.
Zhang X; Wang C; Huang C; Yang J; Wang J
Histol Histopathol; 2023 Oct; 38(10):1193-1204. PubMed ID: 36621840
[TBL] [Abstract][Full Text] [Related]
23. lncRNA profile study reveals the mRNAs and lncRNAs associated with docetaxel resistance in breast cancer cells.
Huang P; Li F; Li L; You Y; Luo S; Dong Z; Gao Q; Wu S; Brünner N; Stenvang J
Sci Rep; 2018 Dec; 8(1):17970. PubMed ID: 30568280
[TBL] [Abstract][Full Text] [Related]
24. LINC00160 mediated paclitaxel-And doxorubicin-resistance in breast cancer cells by regulating TFF3 via transcription factor C/EBPβ.
Wu H; Gu J; Zhou D; Cheng W; Wang Y; Wang Q; Wang X
J Cell Mol Med; 2020 Aug; 24(15):8589-8602. PubMed ID: 32652877
[TBL] [Abstract][Full Text] [Related]
25. Elevated Expression of RIOK1 Is Correlated with Breast Cancer Hormone Receptor Status and Promotes Cancer Progression.
Huang Z; Li X; Xie T; Gu C; Ni K; Yin Q; Cao X; Zhang C
Cancer Res Treat; 2020 Oct; 52(4):1067-1083. PubMed ID: 32599985
[TBL] [Abstract][Full Text] [Related]
26. Tumor-derived exosomes RNA expression profiling identifies the prognosis, immune characteristics, and treatment in HR+/HER2-breast cancer.
Zhou Q; Wang J; Zhang H; Sun L; Liu J; Meng L; Li J
Aging (Albany NY); 2023 Aug; 15(16):8471-8486. PubMed ID: 37647033
[TBL] [Abstract][Full Text] [Related]
27. High levels of DJ-1 protein in nipple fluid of patients with breast cancer.
Oda M; Makita M; Iwaya K; Akiyama F; Kohno N; Tsuchiya B; Iwase T; Matsubara O
Cancer Sci; 2012 Jun; 103(6):1172-6. PubMed ID: 22404125
[TBL] [Abstract][Full Text] [Related]
28. PRKDC regulates chemosensitivity and is a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients.
Sun G; Yang L; Dong C; Ma B; Shan M; Ma B
Oncol Rep; 2017 Jun; 37(6):3536-3542. PubMed ID: 28498431
[TBL] [Abstract][Full Text] [Related]
29. Clinical Theragnostic Relationship between Drug-Resistance Specific miRNA Expressions, Chemotherapeutic Resistance, and Sensitivity in Breast Cancer: A Systematic Review and Meta-Analysis.
Jayaraj R; Nayagam SG; Kar A; Sathyakumar S; Mohammed H; Smiti M; Sabarimurugan S; Kumarasamy C; Priyadharshini T; Gothandam KM; Ramesh N; Gupta A; Baxi S; Swamiappan S; Krishnan S
Cells; 2019 Oct; 8(10):. PubMed ID: 31615089
[TBL] [Abstract][Full Text] [Related]
30. High expression of TRAF4 predicts poor prognosis in tamoxifen-treated breast cancer and promotes tamoxifen resistance.
Zhou J; Li W; Ming J; Yang W; Lu L; Zhang Q; Ruan S; Huang T
Anticancer Drugs; 2020 Jul; 31(6):558-566. PubMed ID: 32304412
[TBL] [Abstract][Full Text] [Related]
31. Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry.
Wirtz RM; Sihto H; Isola J; Heikkilä P; Kellokumpu-Lehtinen PL; Auvinen P; Turpeenniemi-Hujanen T; Jyrkkiö S; Lakis S; Schlombs K; Laible M; Weber S; Eidt S; Sahin U; Joensuu H
Breast Cancer Res Treat; 2016 Jun; 157(3):437-46. PubMed ID: 27220750
[TBL] [Abstract][Full Text] [Related]
32. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
33. Bioinformatics identification of CCL8/21 as potential prognostic biomarkers in breast cancer microenvironment.
Chen B; Zhang S; Li Q; Wu S; He H; Huang J
Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33146700
[TBL] [Abstract][Full Text] [Related]
34. Identification and characterization of three Siglec15-related immune and prognostic subtypes of breast-invasive cancer.
Cao X; Zhou Y; Mao F; Lin Y; Zhou X; Sun Q
Int Immunopharmacol; 2022 May; 106():108561. PubMed ID: 35151947
[TBL] [Abstract][Full Text] [Related]
35. High levels of DJ-1 protein and isoelectric point 6.3 isoform in sera of breast cancer patients.
Kawate T; Iwaya K; Koshikawa K; Moriya T; Yamasaki T; Hasegawa S; Kaise H; Fujita T; Matsuo H; Nakamura T; Ishikawa T; Hiroi S; Iguchi-Ariga SM; Ariga H; Murota K; Fujimori M; Yamamoto J; Matsubara O; Kohno N
Cancer Sci; 2015 Jul; 106(7):938-43. PubMed ID: 25867058
[TBL] [Abstract][Full Text] [Related]
36. PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer.
Munkácsy G; Abdul-Ghani R; Mihály Z; Tegze B; Tchernitsa O; Surowiak P; Schäfer R; Györffy B
Br J Cancer; 2010 Jan; 102(2):361-8. PubMed ID: 20010949
[TBL] [Abstract][Full Text] [Related]
37. The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.
Sánchez-Muñoz A; Plata-Fernández YM; Fernández M; Jaén-Morago A; Fernández-Navarro M; de la Torre-Cabrera C; Ramirez-Tortosa C; Lomas-Garrido M; Llácer C; Navarro-Perez V; Alba-Conejo E; Sánchez-Rovira P
Clin Breast Cancer; 2013 Apr; 13(2):146-52. PubMed ID: 23318089
[TBL] [Abstract][Full Text] [Related]
38. Circular RNA La-related RNA-binding protein 4 correlates with reduced tumor stage, as well as better prognosis, and promotes chemosensitivity to doxorubicin in breast cancer.
Zhang X; Su X; Guo Z; Jiang X; Li X
J Clin Lab Anal; 2020 Jul; 34(7):e23272. PubMed ID: 32187743
[TBL] [Abstract][Full Text] [Related]
39. LncRNA CBR3-AS1 regulates of breast cancer drug sensitivity as a competing endogenous RNA through the JNK1/MEK4-mediated MAPK signal pathway.
Zhang M; Wang Y; Jiang L; Song X; Zheng A; Gao H; Wei M; Zhao L
J Exp Clin Cancer Res; 2021 Jan; 40(1):41. PubMed ID: 33494806
[TBL] [Abstract][Full Text] [Related]
40. Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.
Martin M; Romero A; Cheang MC; López García-Asenjo JA; García-Saenz JA; Oliva B; Román JM; He X; Casado A; de la Torre J; Furio V; Puente J; Caldés T; Vidart JA; Lopez-Tarruella S; Diaz-Rubio E; Perou CM
Breast Cancer Res Treat; 2011 Jul; 128(1):127-36. PubMed ID: 21465170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
